Our study shows that age, the largest size ADC values of the primary tumor on MRI and SUVmax from PET scans are significant prognostic indicators for survival in vulvar cancer patients. Specifically, increased values in these parameters correlated with reduced survival outcomes, except for the ADC values. This study's findings enrich our comprehension of how such parameters can be harnessed to predict survival outcomes more accurately, offering a more nuanced approach to patient care.
Age is a recurring theme in oncological research as a determinant of survival outcomes [8]. Our study reaffirms this relationship, with age emerging as a potent predictor for overall survival in patients with vulvar cancer. This observation aligns with the broader understanding of oncology, where older age often corresponds to a decreased survival rate [8, 9]. The underlying reasons could be manifold. For instance, older patients might have a reduced physiological ability to combat the disease [10], a waning immune response [11], and a higher likelihood of concurrent medical conditions that might complicate treatment or recovery [9, 12].
The significant role of Axial T2 and Sagittal T2 MRI measurements in predicting survival provides valuable insights into the disease's progression. These metrics indicate the primary tumor's size and directly correlate with survival outcomes. As revealed by these measurements, larger tumors might denote a more aggressive disease variant or a prolonged disease course without intervention [13–17]. In a study involving 416 women diagnosed with cervical cancer, MRI tumor size variables yielded high areas under the time-dependent receiver operating characteristics (tdROC) curves for predicting survival five years after diagnosis [13]. Similarly, in lower-grade gliomas, MRI features such as the longest axis length of the tumor were significantly associated with poor survival [17]. It's pertinent to understand the implications of these findings. Tumor size has always been a cornerstone in oncological assessments, acting as a surrogate marker for disease stage, potential metastasis, and overall aggressiveness. Our findings underscore its pivotal role, especially in vulvar cancer, where precise measurements can significantly influence therapeutic decisions.
The SUVmax values, derived from PET scans, can be used as prognostic indicators. This metric is a mirror of the tumor's metabolic activity. A higher SUVmax is often a sign of a tumor with heightened metabolic activity, suggesting a more aggressive phenotype [6, 18–24]. In the context of vulvar cancer, a study demonstrated the prognostic value of SUVmax, with PET/CT imaging significantly impacting treatment decision-making [6]. This aligns with prior studies across various malignancies where an increased SUVmax has been associated with aggressive tumor behavior and, consequently, reduced survival. Our study not only reiterates the prognostic importance of SUVmax in vulvar cancer but also refines its clinical utility by identifying an optimal cutpoint. Such a threshold can be instrumental in stratifying patients into risk categories, thereby guiding clinicians in tailoring therapies more effectively.
The Apparent Diffusion Coefficient (ADC) values, derived from MRI, have been shown to correlate with tumor cellularity and aggressiveness in various types of cancer [25–27]. The ADC values represent the diffusion of water molecules within tissues, and a lower ADC value typically indicates higher cellularity and potentially more aggressive tumors [8, 25, 28]. This correlation has been observed in cancers such as colon cancer, where the ADC value of the primary tumor has been used as a biomarker to predict metastasis [26]. In our study, tumors with ADC value < 1.026 x10− 3 mm2/s had poorer survival, p = 0.0083 (p > 0.05).
Our study showed that metastases to the lungs and bone were rare. Only one patient had bone metastasis. None of the patients had liver metastases or peritoneal disease [29]. Only three patients had retroperitoneal disease.
Another noteworthy aspect of our study was the exploration of size measurements across different imaging modalities. Consistent measures, irrespective of the imaging technique, provide a robust foundation for clinical decision-making [30, 31]. Such uniformity ensures that therapeutic choices often hinge on tumor size remain standardized, irrespective of the imaging modality employed [32, 33]. This is particularly relevant in multi-center trials or settings where patients might undergo imaging at different facilities with varied equipment.
Limitations
While the study provides a comprehensive analysis of the clinical and imaging parameters of vulvar cancer prognosis, there are inherent limitations. The study is based on historical data, which inherently carries potential biases. The data might not account for all possible confounding variables or changes in clinical practices over time. With data from only 45 patients and from a single institution, the findings must be more generalizable to a larger, more diverse population. While the study focused on clinical and imaging parameters, it did not incorporate potential molecular or genetic markers that could have prognostic significance. Though no significant discrepancies were found between imaging techniques, equipment, and protocol variations, especially outside imaging facilities, could introduce subtle biases. Given the specific inclusion criteria, there's potential for selection bias, which could impact the generalizability of the findings. Depending on the duration of the follow-up period, some long-term outcomes or late recurrences might need to be captured. As with any retrospective study, unmeasured confounders could not be accounted for in the analysis. The study relied on imaging (MRI and PET) for metastasis detection, which, while accurate, might not capture micrometastases as effectively as pathological examinations.